SCHEMBL4634871

SCHEMBL4634871

NC1C2CN(c3ccccc3)CC12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BPTF Q12830 1/20 0.50
DPP4 P27487 3/20 0.42
LMNA P02545 2/20 0.40
NOTUM Q6P988 1/20 0.40
HTR3E A5X5Y0 1/20 0.40
HTR3B O95264 1/20 0.40
ADRB1 P08588 1/20 0.40
HTR3A P46098 1/20 0.40
HTR3D Q70Z44 1/20 0.40
HTR3C Q8WXA8 1/20 0.40
SIGMAR1 Q99720 1/20 0.40
DRD4 P21917 1/20 0.39
MBTD1 Q05BQ5 1/20 0.38
L3MBTL3 Q96JM7 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
CHRNA7 P36544 2/20 0.38
CYP3A4 P08684 1/20 0.38
ALOX15 P16050 1/20 0.38
CHRNB2 P17787 1/20 0.38
NFKB1 P19838 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30818891 1.00 BPTF (0.50) BPTFDPP4LMNANOTUMHTR3E
SCHEMBL6990841 0.81 BPTF (0.54) BPTFDPP4LMNANOTUMHTR3E
Hydrochloric Acid SCHEMBL30182618 0.79 BPTF (0.52) BPTFDPP4LMNANOTUMHTR3E
SCHEMBL24624127 0.78 KDM1A (0.38) ALOX15MAPK1MGLLKMT2AKCNH2
SCHEMBL22796086 0.78 KDM1A (0.38) ALOX15MAPK1MGLLKMT2AKCNH2
SCHEMBL4321196 0.78 ALDH1A1 (0.48) LMNANOTUMMAPK1MAPTMEN1
SCHEMBL38664660 0.78 CHKA (0.48) DPP4CYP3A4CYP2D6
SCHEMBL17304860 0.77 BPTF (0.50) BPTFDPP4LMNANOTUMHTR3E
SCHEMBL17294901 0.77 BPTF (0.50) BPTFDPP4LMNANOTUMHTR3E
Hydrochloric Acid SCHEMBL28704276 0.77 KDM1A (0.39) L3MBTL1ALOX15HSD17B10MGLLMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors RANBAXY LABORATORIES LIMITED (IN) 2008-12-04 US disclosed
EP-1931633-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS Ranbaxy Laboratories Limited (IN) 2008-06-18 EP disclosed
WO-2007029086-A2 DERIVATIVES OF 3-AZABICYCLO[3.1.0]HEXANE AS DIPEPTIDYL PEPTIDASE-IV INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2007-03-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080300251-A1 Derivatives of 3-Azabicyclo[3.1.0] Hexane as Dipeptidyl Peptidase-IV Inhibitors DPP4, DPP3, DPP8 BPTF 4465/4885DPP4 1/4885LMNA 3634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.